ストックスクリーナーアプリを入手
4.1243
0.73%
-0.0043
前日終値:
$4.12
開ける：
$4.15
24時間の取引高:
37,905
Relative Volume:
0.13
時価総額：
$8.54M
収益：
-
当期純損益:
$-29.77M
株価収益率:
-0.2696
EPS:
-15.2954
ネットキャッシュフロー:
$-24.23M
1週間 パフォーマンス:
+23.56%
1か月 パフォーマンス:
-43.51%
6か月 パフォーマンス:
-57.92%
1年 パフォーマンス:
-90.86%
1日の値動き範囲:
$4.02
$4.2563
1週間の範囲:
$3.25
$4.3172
52週間の値動き範囲:
$3.13
$91.25
Moleculin Biotech Inc Stock (MBRX) Company Profile
MBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
4.1243 | 8.53M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.17 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
797.25 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.56 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
813.86 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.78 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-09 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-12 | ダウングレード | Maxim Group | Buy → Hold |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
Moleculin Biotech Inc (MBRX) 最新ニュース
Moleculin Biotech regains Nasdaq listing compliance - marketscreener.com
Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements - TipRanks
Moleculin Biotech Regains Nasdaq Compliance - TradingView — Track All Markets
Why Moleculin Biotech Inc. stock remains a top recommendation2026 world cup usa national team round of 32 midfield engines counter attacking tactical prediction breakdown - Улправда
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech’s Wild Ride: Is Tiny-Cap MBRX the Next Viral Moonshot or Total Trap? - AD HOC NEWS
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Biotech enters inducement offer agreements - MSN
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moleculin Biotech begins dosing subjects in combination therapy trial for AML - MSN
Moleculin Biotech amends warrants and reports stockholders’ equity above $10 million - Investing.com Nigeria
Moleculin Biotech amends warrants and reports stockholders’ equity above $10 million By Investing.com - Investing.com South Africa
Moleculin Biotech Amends Warrants to Boost Nasdaq Compliance - TipRanks
Moleculin Biotech Signs Warrant Amendment Agreements With Holders of Series E, F and G Warrants - TradingView — Track All Markets
Moleculin Biotech shares slide after release of pediatric brain tumor trial data - MSN
Why retail investors favor Moleculin Biotech Inc. stockJuly 2025 Movers & Weekly Momentum Stock Picks - Улправда
Will Moleculin Biotech Inc. stock rally after Fed decisions2025 Volatility Report & Long Hold Capital Preservation Tips - Улправда
Will Moleculin Biotech Inc. stock split attract more investorsMarket Performance Report & Safe Capital Growth Plans - Улправда
Moleculin Biotech Earnings Notes - Trefis
Moleculin Biotech (LTS:0K2H) EV-to-OCF : -0.07 (As of Dec. 19, 2025) - GuruFocus
How risky is Moleculin Biotech Inc. (MOL) stock compared to peersJuly 2025 Spike Watch & Target Return Focused Picks - DonanımHaber
Why Moleculin Biotech Inc. (MOL) stock is listed among top recommendationsJuly 2025 PreEarnings & Technical Pattern Based Signals - DonanımHaber
Earnings Report: Why Moleculin Biotech Inc. stock is considered a top pickJuly 2025 Snapshot & Weekly Setup with High ROI Potential - Улправда
Market Review: Why Moleculin Biotech Inc. stock could rally in 2025July 2025 Snapshot & Fast Gain Swing Alerts - DonanımHaber
What technical charts say about Moleculin Biotech Inc. stockMarket Risk Analysis & Smart Swing Trading Alerts - DonanımHaber
Why Moleculin Biotech Inc. stock could rally in 2025Global Markets & Verified Momentum Stock Watchlist - DonanımHaber
Aug Wrap: Why Moleculin Biotech Inc. stock is considered a top pickJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - Улправда
Why Moleculin Biotech Inc. stock is popular among millennialsWeekly Market Outlook & High Accuracy Swing Trade Signals - Улправда
Why hedge funds are buying Moleculin Biotech Inc. stockTrade Risk Summary & Accurate Trade Setup Notifications - ulpravda.ru
Moleculin Biotech reports positive phase 1 trial results - MSN
Moleculin Biotech stock falls after pediatric brain tumor trial results By Investing.com - Investing.com Australia
Moleculin Biotech’s Bold Move: Stock Split Announced - StocksToTrade
Moleculin’s brain cancer drug shows promise in pediatric trial By Investing.com - Investing.com Nigeria
Moleculin Shares Drop 17% Despite Positive Phase 1 WP1066 Data In Pediatric Brain Tumors - Nasdaq
Moleculin Biotech Prepares for 1-for-25 Reverse Split Amidst Clinical Advancements - timothysykes.com
Moleculin Biotech regains Nasdaq compliance - MSN
Moleculin's WP1066 Shows Immune Activity, Favorable Safety In Pediatric Brain Cancer Trial - Nasdaq
Moleculin announces positive phase 1 data for WP1066 in pediatric brain tumors - marketscreener.com
Moleculin Biotech’s Reverse Split Shocks Market - timothysykes.com
Moleculin’s brain cancer drug shows promise in pediatric trial - Investing.com
Moleculin Biotech stock falls after pediatric brain tumor trial results - Investing.com
Moleculin Biotech Reports Positive Phase 1 Trial Results - TipRanks
Moleculin Biotech Reports Positive Phase 1 Trial Results for WP1066 in Pediatric Brain Cancer Treatments - Quiver Quantitative
Moleculin Biotech, Inc. Announces Positive Phase 1 Trial Results for WP1066 - TradingView — Track All Markets
Moleculin Announces Positive Results from Phase 1 Clinical - GlobeNewswire
Moleculin Biotech Inc (MBRX) 財務データ
収益
当期純利益
現金流量
EPS
1.09%
大文字化:
|
ボリューム (24 時間):